TY - JOUR
T1 - Adjuvant regional isolated perfusion with melphalan for patients with clark V melanoma of the extremities
AU - Vrouenraets, Bart C.
AU - Kroon, Bin B.R.
AU - Klaase, Joost M.
AU - Van Gell, Bert N.
AU - Eggermont, Alexander M.M.
AU - Franklin, Hilary R.
PY - 1993/4
Y1 - 1993/4
N2 - From 1978 to 1990, 32 patients with Clark V melanoma were treated by wide excision of the primary and adjuvant regional isolated perfusion with melphalan. M.D. Anderson stage of disease was stage I in 22 and stage IIIb in 10 patients. Five‐year survival rates were 58% and 27%, respectively. Seven patients developed a recurrence in the perfused limb [stage I, 2, stage IIIb, 5 patients (P = 0.03)], and 4 of 17 patients developed regional lymph node metastases. Of the well‐known prognostic variables, only ulceration of the primary tumor significantly influenced survival (P = 0.03). We did not see any improvement in survival rates compared with literature data on nonperfused patients. In the absence of data on locoregional recurrence rates in nonperfused Clark V melanoma patients, we cannot say whether adjuvant perfusion diminished this risk. Therefore, the results of the prospective randomized EORTC/WHO trial in primary high‐risk extremity melanoma have to be awaited. © 1993 Wiley‐Liss, Inc.
AB - From 1978 to 1990, 32 patients with Clark V melanoma were treated by wide excision of the primary and adjuvant regional isolated perfusion with melphalan. M.D. Anderson stage of disease was stage I in 22 and stage IIIb in 10 patients. Five‐year survival rates were 58% and 27%, respectively. Seven patients developed a recurrence in the perfused limb [stage I, 2, stage IIIb, 5 patients (P = 0.03)], and 4 of 17 patients developed regional lymph node metastases. Of the well‐known prognostic variables, only ulceration of the primary tumor significantly influenced survival (P = 0.03). We did not see any improvement in survival rates compared with literature data on nonperfused patients. In the absence of data on locoregional recurrence rates in nonperfused Clark V melanoma patients, we cannot say whether adjuvant perfusion diminished this risk. Therefore, the results of the prospective randomized EORTC/WHO trial in primary high‐risk extremity melanoma have to be awaited. © 1993 Wiley‐Liss, Inc.
KW - disease‐free survival
KW - locoregional recurrence
KW - prognostic factors
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=0027521001&partnerID=8YFLogxK
U2 - 10.1002/jso.2930520411
DO - 10.1002/jso.2930520411
M3 - Article
C2 - 8468989
AN - SCOPUS:0027521001
SN - 0022-4790
VL - 52
SP - 249
EP - 254
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 4
ER -